Protein-coffee company Javvy is exploring a sale that could value the business at about $1 billion, according to people familiar with the matter, as demand for high-protein foods and drinks accelerates alongside the rapid adoption of GLP-1 weight-loss drugs. 

The South Carolina-based company has hired Houlihan Lokey to run an early-stage sale process. No deal is guaranteed, but the valuation being discussed is striking for a brand founded only in 2020. Javvy is generating nearly $300 million in annual revenue and has expanded into major retailers including Walmart, Target and Sprouts Farmers Market. 

What makes the story bigger than coffee is the way weight-loss drugs are beginning to reshape the packaged-food market.

GLP-1 users typically eat less, which initially looked like a threat to food manufacturers and restaurants. But it is also creating demand for products that deliver more protein and nutrition in smaller portions. Javvy’s protein coffee sits directly in that shift, offering caffeine and 10 grams of protein per serving in a format consumers already use daily. 

That gives strategic buyers a reason to pay attention. Large beverage and food companies are looking for faster-growing categories while many traditional packaged-food brands struggle with weak volumes and price-sensitive consumers. A company positioned around protein, convenience and weight-management trends can therefore command a premium even without decades of brand history.

The potential $1 billion valuation would equal a little more than three times Javvy’s reported annual revenue, underscoring how aggressively investors are pricing companies tied to health, functional beverages and changing eating habits.

Javvy also illustrates how quickly digital consumer brands can move into mainstream retail. The company says it now reaches roughly one in every 44 U.S. households and sells a product every seven to eight seconds. 

The deal process is still preliminary. But if Javvy attracts a buyer near the valuation being discussed, it would offer another sign that the GLP-1 economy is beginning to create winners far beyond pharmaceutical companies.

JBizNews Desk | Consumer & Deals

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.